<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04482257</url>
  </required_header>
  <id_info>
    <org_study_id>HE072-BE-002</org_study_id>
    <nct_id>NCT04482257</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.</brief_title>
  <official_title>*Official Title: Randomized, Open-label, Single-dose, Two-sequence, Two-period, Crossover Bioequivalence Trial of Irinotecan Liposome Injection in Patients With Advanced Pancreatic Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC Ouyi Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC Ouyi Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, Open-label, Single-dose, Two-sequence, Two-period, Crossover Bioequivalence Trial&#xD;
      of Irinotecan Liposome Injection in Patients With Advanced Pancreatic Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study was to determine the bioequivalence of two formulations of&#xD;
      Irinotecan Liposome Injection (70mg/m2) in Chinese patients with Advanced Pancreatic Cancer,&#xD;
      under fasting condition. These data were to be evaluated statistically to determine if the&#xD;
      products meet bioequivalence criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0 -190 hours</time_frame>
    <description>Cmax of Total Irinotecan and Free Irinotecan will be measured for the test product (CSPC) or the reference product (Ipsen).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>0 -190 hours</time_frame>
    <description>The exposure of Total Irinotecan and Free Irinotecan from time (0) to the last quantifiable concentration (t) will be measured for the test product (CSPC) or the reference product (Ipsen).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>0 -190 hours</time_frame>
    <description>The exposure of Total Irinotecan and Free Irinotecan from time (0) to infinity (∞) will be calculated for the test product (CSPC) or the reference product (Ipsen).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>0 -190 hours</time_frame>
    <description>The time to maximum concentration will be measured for the test product (CSPC) or the reference product (Ipsen).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>0 -190 hours</time_frame>
    <description>The terminal elimination half-life will be calculated for the test product (CSPC) or the reference product (Ipsen).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>λz</measure>
    <time_frame>0 -190 hours</time_frame>
    <description>The terminal elimination rate constant will be calculated for the test product (CSPC) or the reference product (Ipsen).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>T-R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Irinotecan Liposome Injection (CSPC) 70mg/m2 plus 5-FU/LV, followed by Irinotecan Liposome Injection (Ipsen) 70mg/m2 plus 5-FU/LV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Irinotecan Liposome Injection (Ipsen) 70mg/m2 plus 5-FU/LV, followed by Irinotecan Liposome Injection (CSPC) 70mg/m2 plus 5-FU/LV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan Liposome Injection combined with 5-FU/LV</intervention_name>
    <description>Drug: Irinotecan Liposome Injection 70mg/m2 (CSPC) combined with 5-FU/LV; Drug: Irinotecan Liposome Injection 70mg/m2 (Ipsen, ONIVYDETM) combined with 5-FU/LV;</description>
    <arm_group_label>R-T</arm_group_label>
    <arm_group_label>T-R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent for participation in the trial.&#xD;
&#xD;
          2. Advanced pancreatic cancer diagnosed by histopathology and / or cytology.&#xD;
&#xD;
          3. Age ≥ 18 years, men or women. BMI is above 17.&#xD;
&#xD;
          4. ECOG score 0 to 2.&#xD;
&#xD;
          5. Life expectancy ≥ 3 months.&#xD;
&#xD;
          6. Adequate bone marrow function.&#xD;
&#xD;
          7. Adequate hepatic function.&#xD;
&#xD;
          8. Adequate renal function.&#xD;
&#xD;
          9. Patient with reproductive potential must agree to use adequate contraception from the&#xD;
             signing of informed consent to at least 6 months after the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have a severe allergy or a significant history of hypersensitivity or an&#xD;
             idiopathic reaction attributed to irinotecan or compounds of similar chemical&#xD;
             composition to irinotecan ;&#xD;
&#xD;
          2. Patients who have previously used irinotecan liposomes and experienced treatment&#xD;
             failure or serious adverse reactions;&#xD;
&#xD;
          3. Patients with severe cardiovascular, lung, liver, kidney, gastrointestinal, endocrine,&#xD;
             immune system, skin, musculoskeletal, neurological or psychiatric diseases that&#xD;
             occurred within 3 months of the first dose of the study drug, and not suitable for&#xD;
             this study as determined by the researchers;&#xD;
&#xD;
          4. Patients who have undergone major surgery within 4 weeks of screening or have a&#xD;
             schedule for major surgery during the study period;&#xD;
&#xD;
          5. Patients who have received any radiotherapy or chemotherapy and other anti-tumor&#xD;
             treatment within 4 weeks of the first dose of the study drug, traditional Chinese&#xD;
             medicine with anti-tumor indications within 4 weeks of the first dose of the study&#xD;
             drug, or small molecule targeted drugs within 2 weeks (or 5 half-lives whichever is&#xD;
             longer) of the first dose of the study drug;&#xD;
&#xD;
          6. Patients who currently enrolled in any other clinical study, or received other&#xD;
             investigational agents within 4 weeks of the first dose of the study drug；&#xD;
&#xD;
          7. Blood donation or massive blood loss (&gt;400mL) within 90 days of screening;&#xD;
&#xD;
          8. Concomitant use of strong CYP3A4 inhibitors or inducers, or UGT1A1 inhibitors within 4&#xD;
             weeks of the first dose of the study drug;&#xD;
&#xD;
          9. Patients who received certain diet (such as grapefruit) which may interfere with the&#xD;
             evaluation of PK results;&#xD;
&#xD;
         10. LVEF≤50%;&#xD;
&#xD;
         11. Patients with extended QT/QTc interval (QTcF&gt;480ms);&#xD;
&#xD;
         12. History of alcohol or drugs abuse;&#xD;
&#xD;
         13. Pregnant or lactating women;&#xD;
&#xD;
         14. Patients with known Hepatitis B Virus (HBV DNA≥104), Hepatitis C Virus (anti-HCV&#xD;
             positive, HCV RNA positive), Human immunodeficiency virus antibody (anti-HIV&#xD;
             positive), or active Treponema Pallidum viral infection;&#xD;
&#xD;
         15. Patients with homozygous UGT1A1*28 genotype or UGT1A1*6 genotype;&#xD;
&#xD;
         16. Patients who are not suitable for this study as determined by the researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihui Hao, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xuekun Yao</last_name>
    <phone>0311-67808678</phone>
    <email>yaoxuekun@mail.ecspc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianqiang Song</last_name>
      <phone>022-23340123</phone>
      <phone_ext>6012</phone_ext>
      <email>ec_tjcih@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

